Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$3.83 -0.5%	$3.84	$2.12 ▼ $5.80	$381.94M	1.99	1.52 million shs	1.10 million shs
ATOS Atossa Genetics	$0.75 -1.0%	$0.83	$0.55 ▼ $1.66	$97.41M	0.92	853,359 shs	355,963 shs
OLMA Olema Pharmaceuticals	$5.52 -3.8%	$4.88	$2.86 ▼ $13.93	$378.84M	1.92	854,397 shs	298,887 shs
RCKT Rocket Pharmaceuticals	$3.35 +0.9%	$3.03	$2.19 ▼ $22.01	$361.48M	0.65	3.73 million shs	4.40 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	-1.28%	-0.77%	-3.75%	+37.99%	-16.85%
ATOS Atossa Genetics	-1.78%	+3.11%	-6.80%	+0.13%	-43.59%
OLMA Olema Pharmaceuticals	+0.17%	+5.32%	+18.84%	+8.30%	-50.86%
RCKT Rocket Pharmaceuticals	-2.06%	-11.47%	+6.75%	+26.72%	-82.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AQST Aquestive Therapeutics	2.2332 of 5 stars	3.4	3.0	0.0	4.0	0.0	0.0
ATOS Atossa Genetics	2.5097 of 5 stars	3.7	5.0	0.0	2.2	0.0	0.0
OLMA Olema Pharmaceuticals	1.8195 of 5 stars	3.3	0.0	0.0	3.4	2.5	0.0
RCKT Rocket Pharmaceuticals	4.8551 of 5 stars	4.2	4.0	4.7	2.4	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	2.88	Moderate Buy	$10.14	165.17% Upside
ATOS Atossa Genetics	3.33	Buy	$6.17	711.40% Upside
OLMA Olema Pharmaceuticals	2.67	Moderate Buy	$24.00	331.34% Upside
RCKT Rocket Pharmaceuticals	2.41	Hold	$16.73	401.60% Upside

Current Analyst Ratings Breakdown

Latest ATOS, AQST, OLMA, and RCKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $10.00
8/20/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00
8/14/2025	OLMA Olema Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$28.00 ➝ $29.00
8/13/2025	AQST Aquestive Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2025	OLMA Olema Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $21.00
8/11/2025	OLMA Olema Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
8/11/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
8/8/2025	RCKT Rocket Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $8.00
7/25/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
7/25/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$9.00 ➝ $4.00
7/24/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $12.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$44.13M	8.64	N/A	N/A	($0.73) per share	-5.24
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$0.45 per share	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$5.03 per share	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$3.28 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$44.14M	-$0.70	N/A	N/A	N/A	-147.38%	N/A	-63.87%	11/3/2025 (Estimated)
ATOS Atossa Genetics	-$25.50M	-$0.23	N/A	N/A	N/A	N/A	-40.28%	-37.10%	11/11/2025 (Estimated)
OLMA Olema Pharmaceuticals	-$129.47M	-$1.98	N/A	N/A	N/A	N/A	-42.58%	-38.65%	11/11/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.51	N/A	N/A	N/A	N/A	-65.11%	-55.99%	11/6/2025 (Estimated)

Latest ATOS, AQST, OLMA, and RCKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ATOS Atossa Genetics	-$0.06	-$0.07	-$0.01	-$0.07	N/A	N/A
8/11/2025	Q2 2025	AQST Aquestive Therapeutics	-$0.18	-$0.14	+$0.04	-$0.14	$11.32 million	$10.00 million
8/11/2025	Q2 2025	OLMA Olema Pharmaceuticals	-$0.43	-$0.51	-$0.08	-$0.51	N/A	N/A
8/7/2025	Q2 2025	RCKT Rocket Pharmaceuticals	-$0.57	-$0.59	-$0.02	-$0.62	$4.36 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	3.53	3.18
ATOS Atossa Genetics	N/A	9.17	9.17
OLMA Olema Pharmaceuticals	0.01	11.09	11.09
RCKT Rocket Pharmaceuticals	0.05	6.39	6.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
ATOS Atossa Genetics	12.74%
OLMA Olema Pharmaceuticals	91.78%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	8.35%
ATOS Atossa Genetics	7.60%
OLMA Olema Pharmaceuticals	16.36%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	99.72 million	91.40 million	Optionable
ATOS Atossa Genetics	8	129.17 million	119.35 million	Optionable
OLMA Olema Pharmaceuticals	70	68.63 million	57.41 million	Optionable
RCKT Rocket Pharmaceuticals	240	107.90 million	81.19 million	Optionable

ATOS, AQST, OLMA, and RCKT Headlines

Recent News About These Companies

Elisabeth Bjork Buys 10,000 Shares of Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

August 28 at 8:57 AM | insidertrades.com

AlphaQuest LLC Increases Holdings in Rocket Pharmaceuticals, Inc. $RCKT

August 28 at 5:34 AM | marketbeat.com

Rocket Pharmaceuticals CFO Aaron Ondrey resigns to pursue other opportunities

August 25 at 10:39 PM | msn.com

Wellington Management Group LLP Reduces Stock Holdings in Rocket Pharmaceuticals, Inc. $RCKT

August 25 at 4:42 AM | marketbeat.com

William Blair Issues Negative Forecast for RCKT Earnings

August 24, 2025 | marketbeat.com

Q3 EPS Estimate for Rocket Pharmaceuticals Cut by Analyst

August 23, 2025 | americanbankingnews.com

EMA says Rocket Pharmaceuticals withdraws MA application for Fanskya

August 22, 2025 | msn.com

Rocket Pharmaceuticals: Good News As Clinical Hold Lifted - But Challenges Remain

August 22, 2025 | seekingalpha.com

Rocket Pharmaceuticals (RCKT) Receives a Sell from Goldman Sachs

August 22, 2025 | theglobeandmail.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded to Buy at Bank of America

August 22, 2025 | americanbankingnews.com

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

August 21, 2025 | zacks.com

Rocket Pharmaceuticals' (RCKT) "Buy" Rating Reaffirmed at Chardan Capital

August 21, 2025 | americanbankingnews.com

Rocket Pharmaceuticals announces clinical hold lifted on RP-A501 trial

August 20, 2025 | msn.com

John Militello Sells 7,043 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock

August 20, 2025 | marketbeat.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Insider Sells $33,706.22 in Stock

August 20, 2025 | marketbeat.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) General Counsel Martin Wilson Sells 12,109 Shares

August 20, 2025 | marketbeat.com

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

August 20, 2025 | barrons.com

FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy

August 20, 2025 | benzinga.com

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

August 20, 2025 | reuters.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Insider John Militello Sells 7,043 Shares

August 19, 2025 | insidertrades.com

Jefferies Raises PT on Rocket Pharmaceuticals, Inc. (RCKT) to $3.00; Maintains ‘Hold’ Rating

August 19, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ATOS, AQST, OLMA, and RCKT Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$3.83 -0.02 (-0.52%)

Closing price 04:00 PM Eastern

Extended Trading

$3.87 +0.04 (+1.04%)

As of 05:36 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Atossa Genetics NASDAQ:ATOS

$0.75 -0.01 (-0.97%)

Closing price 04:00 PM Eastern

Extended Trading

$0.77 +0.01 (+1.71%)

As of 05:39 PM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Olema Pharmaceuticals NASDAQ:OLMA

$5.52 -0.22 (-3.83%)

Closing price 04:00 PM Eastern

Extended Trading

$5.67 +0.15 (+2.72%)

As of 05:23 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.35 +0.03 (+0.90%)

Closing price 04:00 PM Eastern

Extended Trading

$3.36 +0.00 (+0.15%)

As of 05:36 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time